Giuseppe Nocentini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4889514/publications.pdf Version: 2024-02-01

		109264	106281
116	4,707	35	65
papers	citations	h-index	g-index
122	122	122	5499
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Diagnostic performance of the Bladder EpiCheck methylation test and photodynamic diagnosis-guided cystoscopy in the surveillance of high-risk non-muscle invasive bladder cancer: A single centre, prospective, blinded clinical trial. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 105.e11-105.e18.	0.8	13
2	Validation in an Independent Cohort of MiR-122, MiR-1271, and MiR-15b as Urinary Biomarkers for the Potential Early Diagnosis of Clear Cell Renal Cell Carcinoma. Cancers, 2022, 14, 1112.	1.7	18
3	Immune modulation via T regulatory cell enhancement: Diseaseâ€modifying therapies for autoimmunity and their potential for chronic allergic and inflammatory diseases—An EAACI position paper of the Task Force on Immunopharmacology (TIPCO). Allergy: European Journal of Allergy and Clinical Immunology. 2021. 76. 90-113.	2.7	24
4	IgG4 induces tolerogenic M2-like macrophages and correlates with disease progression in colon cancer. Oncolmmunology, 2021, 10, 1880687.	2.1	18
5	Immune and Nervous Systems Interaction in Endocrine Disruptors Toxicity: The Case of Atrazine. Frontiers in Toxicology, 2021, 3, 649024.	1.6	29
6	Blood clots and bleeding events following BNT162b2 and ChAdOx1 nCoV-19 vaccine: An analysis of European data. Journal of Autoimmunity, 2021, 122, 102685.	3.0	53
7	Cardiovascular, neurological, and pulmonary events following vaccination with the BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: An analysis of European data. Journal of Autoimmunity, 2021, 125, 102742.	3.0	42
8	Telomeres Increasingly Develop Aberrant Structures in Aging Humans. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2020, 75, 230-235.	1.7	10
9	Beta-carotene, telomerase activity and Alzheimer's disease in old age subjects. European Journal of Nutrition, 2020, 59, 119-126.	1.8	34
10	Detection of urinary miRNAs for diagnosis of clear cell renal cell carcinoma. Scientific Reports, 2020, 10, 21290.	1.6	34
11	Microencapsulated G3C Hybridoma Cell Graft Delays the Onset of Spontaneous Diabetes in NOD Mice by an Expansion of Gitr+ Treg Cells. Diabetes, 2020, 69, 965-980.	0.3	7
12	The firstâ€generation phosphodiesterase 5 inhibitors and their pharmacokinetic issue. Andrology, 2019, 7, 804-817.	1.9	16
13	Identification of 15 T Cell Restricted Genes Evaluates T Cell Infiltration of Human Healthy Tissues and Cancers and Shows Prognostic and Predictive Potential. International Journal of Molecular Sciences, 2019, 20, 5242.	1.8	7
14	Context-Dependent Effect of Glucocorticoids on the Proliferation, Differentiation, and Apoptosis of Regulatory T Cells: A Review of the Empirical Evidence and Clinical Applications. International Journal of Molecular Sciences, 2019, 20, 1142.	1.8	45
15	Engineered Alginate Microcapsules for Molecular Therapy Through Biologic Secreting Cells. Tissue Engineering - Part C: Methods, 2019, 25, 296-304.	1.1	4
16	Novel Immune Targets in Melanoma—Letter. Clinical Cancer Research, 2019, 25, 5422-5423.	3.2	1
17	Comparing biologicals and small molecule drug therapies for chronic respiratory diseases: An <scp>EAACI</scp> Taskforce on Immunopharmacology position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 432-448.	2.7	37
18	Potential effect of tumor-specific Treg-targeted antibodies in the treatment of human cancers: A bioinformatics analysis. Oncolmmunology, 2018, 7, e1387705.	2.1	28

#	Article	IF	CITATIONS
19	Treatment of Autoimmune Diseases and Prevention of Transplant Rejection and Graft-Versus-Host Disease by Regulatory T Cells: The State of the Art and Perspectives. , 2018, , 321-357.		6
20	Glucocorticoid-induced TNFR-related gene (GITR) as a therapeutic target for immunotherapy. Expert Opinion on Therapeutic Targets, 2018, 22, 783-797.	1,5	41
21	The role of GITR singleâ€positive cells in immune homeostasis. Immunity, Inflammation and Disease, 2017, 5, 4-6.	1.3	14
22	Influence of chemotherapeutic drug-related gene polymorphisms on toxicity and survival of early breast cancer patients receiving adjuvant chemotherapy. BMC Cancer, 2017, 17, 502.	1,1	13
23	The Proinflammatory Cytokine GITRL Contributes to TRAIL-mediated Neurotoxicity in the HCN-2 Human Neuronal Cell Line. Current Alzheimer Research, 2017, 14, 1090-1101.	0.7	4
24	Modulation of tumor immunity: a patent evaluation of WO2015026684A1. Expert Opinion on Therapeutic Patents, 2016, 26, 417-425.	2.4	8
25	Are we Able to Harness the Immunomodulatory Power of Cytokines for Novel Autoimmune Disease Treatments?. American Journal of Pharmacology and Toxicology, 2015, 10, 37-39.	0.7	2
26	Glucocorticoid-Induced Tumour Necrosis Factor Receptor-Related Protein: A Key Marker of Functional Regulatory T Cells. Journal of Immunology Research, 2015, 2015, 1-17.	0.9	112
27	A focused Real Time PCR strategy to determine GILZ expression in mouse tissues. Results in Immunology, 2015, 5, 37-42.	2.2	13
28	The Clinical Pharmacology of Past, Present, and Future Glucocorticoids. , 2015, , 43-58.		2
29	The Molecular and Cellular Mechanisms Responsible for the Anti-inflammatory and Immunosuppressive Effects of Glucocorticoids. , 2015, , 25-41.		2
30	GITR+ regulatory T cells in the treatment of autoimmune diseases. Autoimmunity Reviews, 2015, 14, 117-126.	2.5	65
31	L-GILZ binds p53 and MDM2 and suppresses tumor growth through p53 activation in human cancer cells. Cell Death and Differentiation, 2015, 22, 118-130.	5.0	25
32	Expansion of regulatory GITR+CD25low/-CD4+ T cells in systemic lupus erythematosus patients. Arthritis Research and Therapy, 2014, 16, 444.	1.6	47
33	Transcriptional regulation of kinases downstream of the T cell receptor: another immunomodulatory mechanism of glucocorticoids. BMC Pharmacology & amp; Toxicology, 2014, 15, 35.	1.0	23
34	Eicosapentaenoic Acid Activates RAS/ERK/C/EBPÎ ² Pathway through H-Ras Intron 1 CpG Island Demethylation in U937 Leukemia Cells. PLoS ONE, 2014, 9, e85025.	1.1	26
35	Glucocorticoid-Induced Tumor Necrosis Factor Receptor Family-Related Ligand Triggering Upregulates Vascular Cell Adhesion Molecule-1 and Intercellular Adhesion Molecule-1 and Promotes Leukocyte Adhesion. Journal of Pharmacology and Experimental Therapeutics, 2013, 347, 164-172.	1.3	29
36	Characterization of a new regulatory CD4+ T cell subset in primary Sjogren's syndrome. Rheumatology, 2013, 52, 1387-1396.	0.9	63

#	Article	IF	CITATIONS
37	AB0037â€CD4+CD25-GITR+regulatory T cells are expanded in the blood, display suppressive function and are inversely correlated with disease activity in patients with primary SjĶgren's syndrome. Annals of the Rheumatic Diseases, 2013, 71, 639.12-639.	0.5	0
38	Characterization of CD4+ and CD8+ Tregs in a Hodgkin's lymphoma patient presenting with myasthenia-like symptoms. Ideggyogyaszati Szemle, 2013, 66, 343-8.	0.4	2
39	Balance between Regulatory T and Th17 Cells in Systemic Lupus Erythematosus: The Old and the New. Clinical and Developmental Immunology, 2012, 2012, 1-5.	3.3	127
40	The intracellular portion of GITR enhances NGF-promoted neurite growth through an inverse modulation of Erk and NF-κB signalling. Biology Open, 2012, 1, 1016-1023.	0.6	14
41	Pharmacological modulation of GITRL/GITR system: therapeutic perspectives. British Journal of Pharmacology, 2012, 165, 2089-2099.	2.7	74
42	Mechanisms of the antiâ€inflammatory effects of glucocorticoids: genomic and nongenomic interference with MAPK signaling pathways. FASEB Journal, 2012, 26, 4805-4820.	0.2	142
43	Expansion of CD4+CD25-GITR+ regulatory T-cell subset in the peripheral blood of patients with primary SjA¶gren's syndrome: correlation with disease activity. Reumatismo, 2012, 64, 293-8.	0.4	14
44	CD8 ⁺ T Cells: GITR Matters. Scientific World Journal, The, 2012, 2012, 1-7.	0.8	27
45	GITR Gene Deletion and GITR-Fc Soluble Protein Administration Inhibit Multiple Organ Failure Induced by Zymosan. Shock, 2011, 36, 263-271.	1.0	14
46	The glucocorticoidâ€induced TNF receptor familyâ€related protein (GITR) is critical to the development of acute pancreatitis in mice. British Journal of Pharmacology, 2011, 162, 1186-1201.	2.7	20
47	Effect of dietary saturated fatty acids on HNF-4α DNA binding activity and ApoCIII mRNA in sedentary rat liver. Molecular and Cellular Biochemistry, 2011, 347, 29-39.	1.4	13
48	CD4 ⁺ CD25 ^{low} GITR ⁺ cells: A novel human CD4 ⁺ T ell population with regulatory activity. European Journal of Immunology, 2011, 41, 2269-2278.	1.6	54
49	Glucocorticoid-Induced TNFR family Related gene (GITR) enhances dendritic cell activity. Immunology Letters, 2011, 135, 24-33.	1.1	15
50	Eicosapentaenoic Acid Demethylates a Single CpG That Mediates Expression of Tumor Suppressor CCAAT/Enhancer-binding Protein δ in U937 Leukemia Cells. Journal of Biological Chemistry, 2011, 286, 27092-27102.	1.6	70
51	Role of regulatory T cells in rheumatoid arthritis: facts and hypothesis. Autoimmunity Highlights, 2010, 1, 45-51.	3.9	17
52	Neutralization of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Reduces Spinal Cord Injury Damage in Mice. Neuropsychopharmacology, 2010, 35, 1302-1314.	2.8	30
53	Identification of regulatory T cells in systemic lupus erythematosus. Autoimmunity Reviews, 2009, 8, 426-430.	2.5	65
54	The GITRL–GITR system alters TLR-4 expression on DC during fungal infection. Cellular Immunology, 2009, 257, 13-22.	1.4	13

#	Article	IF	CITATIONS
55	GITR: A Modulator of Immune Response and Inflammation. Advances in Experimental Medicine and Biology, 2009, 647, 156-173.	0.8	124
56	Stable depletion of poly (ADP-ribose) polymerase-1 reduces in vivo melanoma growth and increases chemosensitivity. European Journal of Cancer, 2008, 44, 1302-1314.	1.3	40
57	Glucocorticoid-Induced Tumor Necrosis Factor Receptor-Related (GITR)-Fc Fusion Protein Inhibits GITR Triggering and Protects from the Inflammatory Response after Spinal Cord Injury. Molecular Pharmacology, 2008, 73, 1610-1621.	1.0	29
58	Peroxisome Proliferator-Activated Receptor-α Contributes to the Anti-Inflammatory Activity of Glucocorticoids. Molecular Pharmacology, 2008, 73, 323-337.	1.0	59
59	Glucocorticoid-Induced TNFR-Related Protein Lowers the Threshold of CD28 Costimulation in CD8+ T Cells. Journal of Immunology, 2007, 179, 5916-5926.	0.4	83
60	Genetic and pharmacological inhibition of GITRâ€GITRL interaction reduces chronic lung injury induced by bleomycin instillation. FASEB Journal, 2007, 21, 117-129.	0.2	39
61	GITR-GITRL System, A Novel Player in Shock and Inflammation. Scientific World Journal, The, 2007, 7, 533-566.	0.8	53
62	GITR/GITRL: More than an effector T cell co-stimulatory system. European Journal of Immunology, 2007, 37, 1165-1169.	1.6	121
63	Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy. Nature Medicine, 2007, 13, 579-586.	15.2	298
64	Modulation of Acute and Chronic Inflammation of the Lung by GITR and its Ligand. Annals of the New York Academy of Sciences, 2007, 1107, 380-391.	1.8	18
65	Interaction of CTSD and A2M polymorphisms in the risk for Alzheimer's disease. Journal of the Neurological Sciences, 2006, 247, 187-191.	0.3	29
66	Proinflammatory Role of Glucocorticoid-Induced TNF Receptor-Related Gene in Acute Lung Inflammation. Journal of Immunology, 2006, 177, 631-641.	0.4	58
67	Modulation of Pro- and Antiapoptotic Molecules in Double-Positive (CD4+CD8+) Thymocytes following Dexamethasone Treatment. Journal of Pharmacology and Experimental Therapeutics, 2006, 319, 887-897.	1.3	37
68	GITR: a multifaceted regulator of immunity belonging to the tumor necrosis factor receptor superfamily. European Journal of Immunology, 2005, 35, 1016-1022.	1.6	163
69	The Glucocorticoid-Induced Tumor Necrosis Factor Receptor-Related Gene Modulates the Response to Candida albicans Infection. Infection and Immunity, 2005, 73, 7502-7508.	1.0	39
70	Dietary PUFA modulate the expression of proliferation and differentiation markers in Morris 3924A hepatoma cells. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2005, 1737, 138-144.	1.2	4
71	Dietary α-linolenic acid reduces COX-2 expression and induces apoptosis of hepatoma cells. Journal of Lipid Research, 2004, 45, 308-316.	2.0	56
72	Glucocorticoid-induced TNF receptor family gene (GITR) knockout mice exhibit a resistance to splanchnic artery occlusion (SAO) shock. Journal of Leukocyte Biology, 2004, 76, 933-940.	1.5	35

#	Article	IF	CITATIONS
73	Frontline: GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations. European Journal of Immunology, 2004, 34, 613-622.	1.6	320
74	Enhanced expression of hepatic lipogenic enzymes in an animal model of sedentariness. Journal of Lipid Research, 2003, 44, 696-704.	2.0	6
75	Cathepsin D Polymorphism in Italian Elderly Subjects with Sporadic Late-Onset Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2003, 16, 151-155.	0.7	13
76	Role of GITR in activation response of T lymphocytes. Blood, 2002, 100, 350-352.	0.6	172
77	Oxidative Stress and Apoptosis in Immune Diseases. International Journal of Immunopathology and Pharmacology, 2002, 15, 157-164.	1.0	44
78	GITR interacts with the pro-apoptotic protein Siva and induces apoptosis. Cell Death and Differentiation, 2002, 9, 1382-1384.	5.0	94
79	Identification of three novel mRNA splice variants of GITR. Cell Death and Differentiation, 2000, 7, 408-410.	5.0	32
80	Gene Structure and Chromosomal Assignment of Mouse GITR, a Member of the Tumor Necrosis Factor/Nerve Growth Factor Receptor Family. DNA and Cell Biology, 2000, 19, 205-217.	0.9	27
81	Glucocorticoid hormones in the regulation of cell death. Therapie, 2000, 55, 165-9.	0.6	32
82	Angiotensin converting enzyme deletion allele in different kinds of dementia disorders. Neuroscience Letters, 1999, 267, 97-100.	1.0	55
83	TCR kappa, a new splicing of the murine TCR zeta gene locus, is modulated by glucocorticoid treatment. Molecular and Cellular Biochemistry, 1999, 195, 47-53.	1.4	4
84	Design and Synthesis of Modified Quinolones as Antitumoral Acridones. Journal of Medicinal Chemistry, 1999, 42, 2136-2144.	2.9	34
85	Genetic polymorphisms (hind III-LPL, Sst I-apo-CIII and APO-E) influence post-prandial lipemia. Atherosclerosis, 1999, 144, 19.	0.4	0
86	Glucocorticoids: regulation of gene expression and apoptosis. Journal of Chemotherapy, 1998, 10, 187-191.	0.7	2
87	A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 6216-6221.	3.3	385
88	Apolipoprotein-E genotype in normal aging, age-associated memory impairment, Alzheimer's disease and vascular dementia patients. Neuroscience Letters, 1997, 231, 59-61.	1.0	30
89	Antitumor activity of 2,2′-bipyridyl-6-carbothioamide: a ribonucleotide reductase inhibitor. General Pharmacology, 1997, 29, 701-706.	0.7	9
90	Short-Term Dexamethasone Treatment Modulates the Expression of the Murine TCRζ Gene Locus. Cellular Immunology, 1997, 178, 124-131.	1.4	7

#	Article	IF	CITATIONS
91	Effect of dexamethasone on T-cell receptor/CD3 expression. Molecular and Cellular Biochemistry, 1997, 167, 135-144.	1.4	12
92	The 2,2′-Bipyridyl-6-carbothioamide copper (II) complex differs from the iron (II) complex in its biochemical effects in tumor cells, suggesting possible differences in the mechanism leading to cytotoxicity. Biochemical Pharmacology, 1996, 52, 65-71.	2.0	13
93	Ribonucleotide reductase inhibitors: new strategies for cancer chemotherapy. Critical Reviews in Oncology/Hematology, 1996, 22, 89-126.	2.0	95
94	Dexamethasone modulates CD2 expression. International Journal of Immunopharmacology, 1996, 18, 677-684.	1.1	0
95	Tumor Cell Death Induced through the Receptor for Interleukin-2. International Journal of Immunopathology and Pharmacology, 1995, 8, 161-172.	1.0	0
96	T cell receptor Î ¹ an alternatively spliced product of the T cell receptor ζ gene. European Journal of Immunology, 1995, 25, 1405-1409.	1.6	13
97	Chelating agents as potential antitumorals. 2-quinolylhydrazones and bis-2-quinolylhydrazones. I. European Journal of Medicinal Chemistry, 1995, 30, 547-552.	2.6	15
98	Furanfurin and Thiophenfurin: Two Novel Tiazofurin Analogs. Synthesis, Structure, Antitumor Activity, and Interactions with Inosine Monophosphate Dehydrogenase. Journal of Medicinal Chemistry, 1995, 38, 3829-3837.	2.9	103
99	Synthesis, Antitumor Activity and Crystallographic Studies of Analogues of Tiazofurin. Nucleosides, Nucleotides and Nucleic Acids, 1995, 14, 637-640.	0.4	5
100	In vitro evaluation of the potential antitumor activity of an N-acridyl-pentanoyloxypyridine-2-thione derivative. Arzneimittelforschung, 1995, 45, 1127-30.	0.5	0
101	A predictive screening model for in vitro selection of agents with potential antitumor activity. Arzneimittelforschung, 1995, 45, 1306-11.	0.5	0
102	Dexamethasone and interleukins modulate apoptosis of murine thymocytes and peripheral T-lymphocytes. Pharmacological Research, 1994, 30, 43-52.	3.1	26
103	8-Aza Derivatives of 3-Deazapurine Nucleosides. Synthesis and <i>in vitro</i> Evaluation of Antiviral and Antitumor Activity. Antiviral Chemistry and Chemotherapy, 1993, 4, 341-352.	0.3	7
104	2,2'-Bipyridyl-6-carbothioamide and its ferrous complex: their in vitro antitumoral activity related to the inhibition of ribonucleotide reductase R2 subunit. Cancer Research, 1993, 53, 19-26.	0.4	154
105	8-Aza Analogues of Deaza Purine Nucleosides. Synthesis and Biological Evaluation of 8-Aza-1-deazaadenosine and 2′-Deoxy-8-aza-1-deazaadenosine. Nucleosides & Nucleotides, 1992, 11, 1059-1076.	0.5	14
106	Copper complex of a new ribonucleotide reductase inhibitor characterized by antitumoral properties. Pharmacological Research, 1992, 25, 312-313.	3.1	5
107	Synthesis and Evaluation of Anti-HIV-1 and Antitumor Activity of 2′,3′-didehydro-2′,3′-dideoxy-3-deazaadenosine, 2′,3′-dideoxy-3-Deazaadenosine and Some 2′,3′-dideoxy-3-deaza-adenosine 5′-dialkyl Phosphates ¹ . Nucleosides & Nucleotides, 1991, 1551-1562.	10 <mark>,0.5</mark>	5
108	Isolation of two cellular lines resistant to ribonucleotide reductase inhibitors to investigate the inhibitory activity of 2,2-bipyridyl-6-carbothioamide. Anti-Cancer Drugs, 1990, 1, 171-178.	0.7	9

7

#	Article	IF	CITATIONS
109	Implications and problems in analysing cytotoxic activity of hydroxyurea in combination with a potential inhibitor of ribonucleotide reductase. Cancer Chemotherapy and Pharmacology, 1990, 26, 345-351.	1.1	6
110	Synthesis and antitumor activity of 2betaD-ribofuranosyloxazole-4-carboxamide (oxazofurin). Journal of Medicinal Chemistry, 1990, 33, 2849-2852.	2.9	26
111	Early evaluation of a new 2,2′-bipyridyl derivative with potential inhibitory activity on the ribonucleotide reductase enzyme. Pharmacological Research, 1990, 22, 364.	3.1	0
112	Implications and problems in analysing cytotoxic activity of hydroxyurea in combination with a potential inhibitor of ribonucleotide reductase*1. Pharmacological Research, 1990, 22, 39-40.	3.1	0
113	Use of P388 line resistant to ribonucleotide reductase inhibitors in a preliminary investigation of 2,2′-bipyridil-6-carbothioamide activity. European Journal of Pharmacology, 1990, 183, 585-586.	1.7	3
114	3,7-Dideazapurine nucleosides. Synthesis and antitumor activity of 1-deazatubercidin and 2-chloro-2'-deoxy-3,7-dideazaadenosine. Journal of Medicinal Chemistry, 1989, 32, 1463-1466.	2.9	10
115	Antiproliferative evaluation of 2,2′-bipyridyl-6-carbothioa mide (Bpyta) and its copper complex [Cu(II)Bpyta] on primary cultures of human acute leukemia cells. Pharmacological Research Communications, 1988, 20, 205.	0.2	2
116	Comparison of in vitro cytotoxicity of 2,2′-bipyridyl (bpy) derivatives and hydroxyurea (HU), on p388 murine leukemia. Pharmacological Research Communications, 1988, 20, 269.	0.2	0